ReviewEuropean respiratory review : an official journal of the European Respiratory Society2022
WASOG statement on the diagnosis and management of sarcoidosis-associated pulmonary hypertension.
Review in European respiratory review : an official journal of the European Respiratory Society, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 59 citations in OpenAlex.
- Treatable traits approach for personalised management of sarcoidosis.BMJ open respiratory research · 2026Review
- Evolution of Exercise Training in Patients with Pulmonary Hypertension-A Comprehensive Review.Healthcare (Basel, Switzerland) · 2026Review
- Contemporary management of sarcoidosis.Frontiers in medicine · 2026Review
- The Mirage of Individualized Therapy in the United States: Barriers in Pulmonary Hypertension Due to Sickle Cell Disease and Sarcoidosis.American journal of respiratory and critical care medicine · 2025Article
- Pulmonary hypertension associated with sarcoidosis: current and future treatment landscape.Future cardiology · 2025Article
- Advanced Pulmonary Sarcoidosis: Treatment and Monitoring.Diagnostics (Basel, Switzerland) · 2025Review
- CT Imaging Features of Pulmonary Sarcoidosis: Typical and Atypical Radiological Features and Their Differential Diagnosis.Medicina (Kaunas, Lithuania) · 2025Review
- [Sarcoidosis].Radiologie (Heidelberg, Germany) · 2025Review
- WASOG Clinical Trial Endpoint Task Force: Executive Summary.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2025Article
- Epidemiology, Clinical Features and Treatment of Neurosarcoidosis in Northern Spain.Biomedicines · 2025Article
- The role of lactate metabolism and lactylation in pulmonary arterial hypertension.Respiratory research · 2025Review
- Pathological diversity of pulmonary sarcoidosis.Frontiers in medicine · 2025Review
- Rheumatologic Perspectives on Sarcoidosis: Predicting Sarcoidosis-Associated Arthritis Through Comprehensive Clinical and Laboratory Assessment.Journal of clinical medicine · 2024Article
- Pulmonary hypertension associated with lung diseases.The European respiratory journal · 2024Review
- [Position paper of the Austrian Society for Rheumatology and the Austrian Society for Pneumology on the diagnosis and treatment of sarcoidosis 2024].Wiener klinische Wochenschrift · 2024Article
- Sarcoidosis-associated pulmonary hypertension due to pulmonary arteries stenosis - a case report.BMC pulmonary medicine · 2024Article
- Sarcoidosis-Associated Pulmonary Hypertension.Journal of clinical medicine · 2024Review
- Use of pulmonary arterial hypertension therapies in patient swith sarcoidosis-associated pulmonary hypertension.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2024Article
- High-Risk Sarcoidosis: A Focus on Pulmonary, Cardiac, Hepatic and Renal Advanced Diseases, as Well as on Calcium Metabolism Abnormalities.Diagnostics (Basel, Switzerland) · 2024Review
- Sarcoidosis Associated Pulmonary Hypertension.Biomedicines · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 9 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sarcoidosis-associated pulmonary hypertension (SAPH) is an important complication of advanced sarcoidosis. Over the past few years, there have been several studies dealing with screening, diagnosis and treatment of SAPH. This includes the results of two large SAPH-specific registries. A task force was established by the World Association of Sarcoidosis and Other Granulomatous disease (WASOG) to summarise the current level of knowledge in the area and provide guidance for the management of patients. A group of sarcoidosis and pulmonary hypertension experts participated in this task force. The committee developed a consensus regarding initial screening including who should undergo more specific testing with echocardiogram. Based on the results, the committee agreed upon who should undergo right-heart catheterisation and how to interpret the results. The committee felt there was no specific phenotype of a SAPH patient in whom pulmonary hypertension-specific therapy could be definitively recommended. They recommended that treatment decisions be made jointly with a sarcoidosis and pulmonary hypertension expert. The committee recognised that there were significant defects in the current knowledge regarding SAPH, but felt the statement would be useful in directing future studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.